Are Patients with Prostate Imaging Reporting and Data System 5 Lesions Eligible for Active Surveillance? A Multicentric European Study.

Date publication

février 2025

Journal

European urology oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr TRICARD Thibault

Tous les auteurs :
Peyrottes A, Baboudjian M, Diamand R, Ducrot Q, Vitard C, Baudewyns A, Windisch O, Anract J, Dariane C, Tricard T, Sarkis J, Sadreux Y, Oderda M, Depaquit TL, La Taille A, Olivier J, Brureau L, Rouviere O, Crouzet S, Ruffion A, Desgrandchamps F, Roumiguie M, Rouprêt M, Ploussard G, Fiard G,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39965998

Résumé

Patients with Prostate Imaging Reporting and Data System (PI-RADS) 5 lesions are at a high risk of clinically significant prostate cancer (PCa), extracapsular extension, and biochemical recurrence (BCR) after local treatment. Managing these patients with active surveillance (AS) can be particularly challenging when targeted biopsies indicate favorable-risk tumors. This study aims to evaluate the outcomes of patients with PI-RADS 5 lesions managed with AS.

Mots clés

Active surveillance, Biopsy reclassification, Magnetic resonance imaging, Prostate Imaging Reporting and Data System, Prostate cancer, Risk stratification

Référence

Eur Urol Oncol. 2025 02 17;: